6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Brain metastasis in pancreatic cancer : Two case reports

      case-report
      , MD, PhD a , b , , , MD b , , MD, PhD b , , MD, PhD a , , MD, PhD b , c , , MD, PhD b
      Medicine
      Wolters Kluwer Health
      brain metastasis, pancreatic cancer, prognosis, treatment

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Rationale:

          Brain metastases are extremely rare for patients with pancreatic adenocarcinoma due to the poor prognoses. In the present study, we reported 2 cases of pancreatic adenocarcinoma with brain metastases.

          Patient concerns:

          The 1st patient was diagnosed asymptomatic brain metastasis by a follow-up brain magnetic resonance imaging (MRI) due to a medical history of subarachnoid hemorrhage. The 2nd patient experienced dizziness, neck pain, and seizure. Computed tomography (CT) was used for the diagnosis of brain metastasis because he was inserted a pacemaker.

          Diagnosis:

          In case 1, brain MRI revealed that a solitary brain metastasis 14-mm in size was identified at the cortico-medullary junction in the left frontal lobe. In case 2, brain enhanced CT revealed multiple brain metastases with calcification at the cerebral cortex. Times to develop central nervous system metastasis were 19 months and 33 months, respectively.

          Interventions:

          The 1st patient was treated with 45.2 Gy γ-knife irradiation for the solitary brain metastasis, and the 2nd patient was treated with supportive care due to the poor general condition.

          Outcomes:

          The prognoses of these 2 patients were 13 months, and 32 days from the diagnosis of brain metastasis. The 1st patient did not experience complication of a γ-knife irradiation and brain metastasis was controlled until death.

          Lessons:

          The incidence of brain metastases from pancreatic adenocarcinoma is expected to increase due to prolonged survival from improved treatment. Therefore, increased awareness of brain involvement is necessary when neurological disorder is suspected in patients with advanced pancreatic cancer.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: not found

          Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.

          Population-based estimates of the incidence of brain metastases are not generally available. The purpose of this study was to calculate population-based incidence proportions (IPs) of brain metastases from single primary lung, melanoma, breast, renal, or colorectal cancer. Patients diagnosed with single primary lung, melanoma, breast, renal, or colorectal cancer (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System (MDCSS) were used for analysis. IP of brain metastases by primary site and variable of interest (race, sex, age at diagnosis of primary cancer, and Surveillance, Epidemiology, and End Results [SEER] stage of primary cancer) was calculated with 95% CIs. Total IP percentage (IP%) of brain metastases was 9.6% for all primary sites combined, and highest for lung (19.9%), followed by melanoma (6.9%), renal (6.5%), breast (5.1%), and colorectal (1.8%) cancers. Racial differences were seen with African Americans demonstrating higher IP% of brain metastases compared with other racial groups for most primary sites. IP% was significantly higher for female patients with lung cancer, and significantly higher for male patients with melanoma. The highest IP% of brain metastases occurred at different ages at diagnoses: age 40 to 49 years for primary lung cancer; age 50 to 59 years for primary melanoma, renal, or colorectal cancers; and age 20 to 39 for primary breast cancer. IP% significantly increased as SEER stage of primary cancer advanced for all primary sites. Total IP% of brain metastases was lower than previously reported, and it varied by primary site, race, sex, age at diagnosis of primary cancer, and SEER stage of primary cancer.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.

            Brain metastases (BM) occur frequently in many cancers, particularly non-small cell lung cancer (NSCLC), breast cancer, and melanoma. The development of BM is associated with poor prognosis and has an adverse impact on survival and quality of life. Commonly used therapies for BM such as surgery or radiotherapy are associated with only modest benefits. However, recent advances in systemic therapy of many cancers have generated considerable interest in exploration of those therapies for treatment of intracranial metastases.This review discusses the epidemiology of BM from the aforementioned primary tumors and the challenges of using systemic therapies for metastatic disease located within the central nervous system. Cumulative data from several retrospective and small prospective studies suggest that molecularly targeted systemic therapies may be an effective option for the treatment of BM from NSCLC, breast cancer, and melanoma, either as monotherapy or in conjunction with other therapies. Larger prospective studies are warranted to further characterize the efficacy and safety profiles of these targeted agents for the treatment of BM.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.

              To provide formal expert consensus-based recommendations to practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer.
                Bookmark

                Author and article information

                Journal
                Medicine (Baltimore)
                Medicine (Baltimore)
                MEDI
                Medicine
                Wolters Kluwer Health
                0025-7974
                1536-5964
                January 2019
                25 January 2019
                : 98
                : 4
                : e14227
                Affiliations
                [a ]Department of Gastroenterology, Cancer Institute Hospital of Japanese Foundation of Cancer Research
                [b ]Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo
                [c ]Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
                Author notes
                []Correspondence: Takashi Sasaki, Department of Gastroenterology, Cancer Institute Hospital of Japanese Foundation of Cancer Research. 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan (e-mail: sasakit-tky@ 123456umin.ac.jp ).
                Article
                MD-D-18-06638 14227
                10.1097/MD.0000000000014227
                6358345
                30681602
                f01afedc-5cf3-49b5-802e-808a550167c0
                Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.

                This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

                History
                : 25 September 2018
                : 23 December 2018
                : 1 January 2019
                Categories
                4500
                Research Article
                Clinical Case Report
                Custom metadata
                TRUE

                brain metastasis,pancreatic cancer,prognosis,treatment
                brain metastasis, pancreatic cancer, prognosis, treatment

                Comments

                Comment on this article